DNA or not DNA -that is the question determining the design of platinum anticancer drugs

Area of Science:

• Oncology and Medicinal Chemistry

Background:

• Platinum-based chemotherapy is a cornerstone in cancer treatment, primarily targeting cancer cell apoptosis through DNA binding.
• The traditional understanding of platinum drug mechanisms has limited the development of novel anticancer agents.
• Emerging evidence suggests alternative mechanisms beyond DNA interaction are crucial for platinum drug efficacy.

Purpose of the Study:

• To challenge the classical DNA-binding paradigm for platinum-based anticancer drugs.
• To explore diverse mechanisms of action for platinum complexes in cancer therapy.
• To identify new avenues for designing innovative platinum anticancer drugs.

Main Methods:

• Review of current literature on platinum complex mechanisms of action.
• Analysis of studies demonstrating non-covalent DNA interactions and protein binding by platinum complexes.
• Evaluation of evidence for platinum complex activity through interactions with cellular components and systems.

Main Results:

• Many platinum complexes exhibit antitumor activity via non-covalent DNA adducts or protein interactions, not solely covalent DNA binding.
• Antitumor effects can be mediated by interactions with biomolecules, organelles, signaling pathways, and the immune system.
• Covalent DNA binding is not essential for the anticancer efficacy of all platinum complexes.

Conclusions:

• The anticancer activity of platinum complexes is not limited to covalent DNA binding.
• Diverse molecular and cellular interactions contribute to the efficacy of platinum-based drugs.
• Rethinking the mechanism of action opens new strategies for designing next-generation platinum anticancer drugs.